Trials / Unknown
UnknownNCT02328261
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma: A Phase II, Multi-center, Open-label Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.
Detailed description
This phase 2 study is aimed to evaluate the efficacy of single-agent icotinib in patients with pretreated, advanced nasopharyngeal carcinoma. The primary endpoint is disease control rate (DCR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icotinib | Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity. |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2016-10-01
- Completion
- 2017-04-01
- First posted
- 2014-12-31
- Last updated
- 2014-12-31
Source: ClinicalTrials.gov record NCT02328261. Inclusion in this directory is not an endorsement.